Obesity is associated with an increased risk of venous thromboembolism (VTE), including during the perioperative period of bariatric surgery. The effectiveness of various methods of perioperative prevention of VTE is discussed in this review.

1. Fontaine GV, Vigil E, Wohlt PD, et al. Venous thromboembolism in critically ill medical patients receiving chemoprophylaxis: a focus on obesity and other risk factors / Clin Appl Thromb Hemost. – 2016. – V. 22. – P. 265–273.

2. Freeman AL, Pendleton RC, Rondina MT. Prevention of venous thromboembolism in obesity / Expert Rev Cardiovasc Ther. – 2010. – V. 8. – P. 1711–1721.

3. Froehling DA, Daniels PR, Mauck KF, et al. Incidence of venous thromboembolism after bariatric surgery: a population-based cohort study / Obes Surg. – 2013. – V. 23. – P. 1874–1879.

4. Steele KE, Schweitzer MA, Prokopowicz G, et al. The long-term risk of venous thromboembolism following bariatric surgery / Obes. Surg. – 2011. – V. 21. – P. 1371–1376.

5. Bartlett MA, Mauck KF, Daniels PR. Prevention of venous thromboembolism in patients undergoing bariatric surgery / Vasc Health Risk Manag. – 2015. – V. 11. – P. 461–477.

6. Gagner M, Selzer F, Belle SH, et al. Adding chemoprophylaxis to sequential compression might not reduce risk of venous thromboembolism in bariatric surgery patients / Surg Obes Relat Dis. – 2012. – V. 8. – P. 663–670.

7. Frantzides CT, Welle SN, Ruff TM, Frantzides AT. Routine anticoagulation for venous thromboembolism prevention following laparoscopic gastric bypass / JSLS. – 2012. – V. 16. – P. 33–37.

8. Birkmeyer NJ, Finks JF, Carlin AM, et al. Comparative effectiveness of unfractionated and low-molecular-weight heparin for prevention of venous thromboembolism following bariatric surgery / Arch Surg. – 2012. – V. 147. – P. 994–998.

9. Kothari SN, Lambert PJ, Mathiason MA. Best Poster Award. A comparison of thromboembolic and bleeding events following laparoscopic gastric bypass in patients treated with prophylactic regimens of unfractionated heparin or enoxaparin / Am J Surg. – 2007. – V. 194. – P. 709–711.

10. Steele KE. The EFFORT trial: preoperative enoxaparin versus postoperative fondaparinux for thromboprophylaxis in bariatric surgical patients: a randomized double-blind pilot trial / Surg Obes Relat Dis. – 2015. – V. 11. – P. 672–683.

11. Imberti D, Baldini E, Pierfranceschi MG, et al. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study) / Obes Surg. – 2014. – V. 24. – P. 284–291.

12. Kalfarentzos F, Stavropoulou F, Yarmenitis S, et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial / Obes Surg. – 2001. – V. 11. – P. 670–676.

13. Scholten DJ, Hoedema RM, Scholten SE. A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery / Obes Surg. – 2002. – V. 12. – P. 19–24.

14. Hamad GG, Choban PS. Enoxaparin for thromboprophylaxis in morbidly obese patients undergoing bariatric surgery: findings of the prophylaxis against VTE outcomes in bariatric surgery patients receiving enoxaparin (PROBE) study / Obes Surg. – 2005. – V. 15. – P. 1368–1374.

15. Borkgren-Okonek MJ, Hart RW, Pantano JE, et al. Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity / Surg Obes Relat Dis. – 2008. – V. 4. – P. 625–631.

16. Woo HD, Kim YJ. Prevention of venous thromboembolism with enoxaparin in bariatric surgery / J Korean Surg Soc. – 2013. – V. 84. – P. 298–303.

17. Shelkrot M, Miraka J, Perez ME. Appropriate enoxaparin dose for venous thromboembolism prophylaxis in patients with extreme obesity / Hosp Pharm. – 2014. – V. 49. – P. 740–747.

18. Simone EP, Madan AK, Tichansky DS, et al. Comparison of two low-molecular-weight heparin dosing regimens for patients undergoing laparoscopic bariatric surgery / Surg Endosc. – 2008. – V. 22. – P. 2392–2395.

19. Freeman A, Horner T, Pendleton RC, Rondina MT. Prospective comparison of three enoxaparin dosing regimens to achieve target antifactor Xa levels in hospitalized, medically ill patients with extreme obesity / Am J Hematol. – 2012. – V. 87. – P. 740–743.

20. Raftopoulos I, Martindale C. The effect of extended postdischarge chemical thromboprophylaxis on venous thromboembolism rates after bariatric surgery: a prospective comparison trial / Surg Endosc. – 2008. – V. 22. – P. 2384–2391.

21. Cossu ML, Pilo L, Piseddu G, et al. Prophylaxis of venous thromboembolism in bariatric surgery / Chir Ital. – 2007. – V. 59. – P. 331–335.

22. Heffline MS. Preventing vascular complications after gastric bypass / J Vasc Nurs. – 2006. – V. 24:50–54.

23. Ojo P, Asiyanbola B, Valin E. Post discharge prophylactic anticoagulation in gastric bypass patient-how safe? / Obes Surg. – 2008. – V. 18. – P. 791–796.

24. Li W, Gorecki P, Semaan E, et al. Concurrent prophylactic placement of inferior vena cava filter in gastric bypass and adjustable banding operations in the Bariatric Outcomes Longitudinal Database / J Vasc Surg. – 2012. – V. 55. – P. 1690–1695.

25. Overby DW, Kohn GP, Cahan MA, et al. Riskgroup targeted inferior vena cava filter placement in gastric bypass patients / Obes Surg. – 2009. – V. 19. – P. 451–455.

26. Rowland SP, Dharmarajah B, Moore HM, et al. Inferior vena cava filters for prevention of venous thromboembolism in obese patients undergoing bariatric surgery: a systematic review / Ann Surg. – 2015. – V. 261. – P. 35–45.

27. Wang TF. Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients / Thromb Haemost. – 2014. – V. 111. – P. 88–93.

28. Vandiver JW, Ritz LI, Lalama JT. Chemical prophylaxis to prevent venous thromboembolism in morbid obesity: literature review and dosing recommendations / J Thromb Thrombolysis. – 2016. – V. 41. – P. 475–481.

29. Ihaddadene R, Carrier M. The use of anticoagulants for the treatment and prevention of venous thromboembolism in obese patients: implications for safety / Expert Opin Drug Saf. – 2016. – V. 15. – P. 65–74.